How to Get Vyleesi in North Dakota

Telehealth Prescribing Is Legal in North Dakota

North Dakota permits telehealth prescribing of Vyleesi without geographic restriction within state lines. Any provider holding an active North Dakota medical license can evaluate, diagnose HSDD, and prescribe bremelanotide via synchronous audio-video visit.

The North Dakota Board of Medicine recognizes telehealth as an accepted standard of care under NDCC 43-17-01, and the state maintained permanent telehealth flexibilities after the federal public health emergency ended in 2023. This means a patient in Bismarck, Fargo, Grand Forks, or any rural community has the same access pathway. The prescriber must establish a valid provider-patient relationship during the initial consultation, which typically takes 20 to 40 minutes and includes sexual health history, medication reconciliation, and blood pressure documentation 1.

Nurse practitioners in North Dakota hold full practice authority after completing a two-year, 2,000-hour collaborative period. After that threshold, NPs can independently prescribe Schedule III through V medications and non-controlled drugs like bremelanotide without physician oversight. Physician assistants may also prescribe under their collaborative agreement.

Step-by-Step Prescription Process

Getting Vyleesi involves four discrete steps: clinical evaluation, lab clearance, prescription issuance, and pharmacy fulfillment. The timeline from first appointment to injection pen in hand is typically 7 to 14 days.

1. Clinical evaluation. The prescriber confirms a diagnosis of HSDD using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R) score of 15 or above and the Decreased Sexual Desire Screener. They rule out medication-induced causes (SSRIs, hormonal contraceptives, antihypertensives) and relationship or mood disorders that better explain low desire.

2. Baseline labs. The FDA label requires blood pressure measurement before prescribing. Most clinicians also order a basic metabolic panel, TSH, prolactin, and total testosterone to exclude endocrine causes. A resting blood pressure above 140/90 mmHg disqualifies use until controlled, because bremelanotide transiently raises systolic BP by a mean of 6 mmHg and heart rate by 7 bpm 2.

3. Prescription. Once cleared, the prescriber sends the electronic prescription to the patient's chosen specialty pharmacy or 503A compounding pharmacy.

4. Fulfillment. The pharmacy dispenses branded Vyleesi autoinjectors (1.75 mg/dose) or, through 503A compounding, patient-specific bremelanotide vials for subcutaneous self-injection.

Lab Requirements Before Starting

Blood pressure is the single mandatory pre-treatment parameter per the Vyleesi prescribing information. Bremelanotide activates melanocortin-4 receptors, which produce a transient pressor effect peaking about 2 to 3 hours after injection 1.

In the RECONNECT trials (two Phase 3 studies, combined N=1,247), mean systolic blood pressure rose 6.1 mmHg and diastolic rose 3.1 mmHg above placebo, returning to baseline within 12 hours 2. The FDA contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease.

Beyond the mandatory BP check, responsible HSDD workups in North Dakota typically include:

• TSH (hypothyroidism suppresses libido in 5 to 15% of premenopausal women with low desire)
• Free and total testosterone
• Prolactin (hyperprolactinemia accounts for roughly 1 to 2% of HSDD presentations)
• CBC if fatigue is a prominent symptom
• Hepatic panel if concurrent medications raise concern for drug metabolism changes

These labs can be drawn at any Quest, Labcorp, or hospital outpatient lab across North Dakota. Results are usually available within 48 hours and can be reviewed during a follow-up telehealth visit.

Clinical Evidence: The RECONNECT Trials

The FDA approved bremelanotide in June 2019 based on the RECONNECT program, two identically designed Phase 3, randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with generalized acquired HSDD 2.

Participants self-administered bremelanotide 1.75 mg subcutaneously as needed before anticipated sexual activity for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index-desire domain (FSFI-D) score and the FSDS-R Item 13 ("bothered by low sexual desire") score.

Results showed:

• FSFI-D improvement: +0.5 points over placebo (P<0.001 in both studies)
• FSDS-R Item 13 reduction: -0.7 points over placebo (P<0.001)
• 34.9% of bremelanotide-treated women achieved a clinically meaningful response on FSFI-D vs. 22.5% on placebo
• Median doses used: 4 to 5 per month, suggesting real-world use is intermittent

The most common adverse event was nausea (40% vs. 1% placebo), which decreased with subsequent doses. Focal hyperpigmentation occurred in 1% of patients, predominantly those with darker baseline skin tones, and was reversible upon discontinuation 1.

Pharmacy Options in North Dakota

North Dakota patients have three pharmacy fulfillment pathways: specialty pharmacy networks, 503A compounding pharmacies, and retail chains with specialty counters.

Specialty pharmacy networks. Branded Vyleesi (autoinjector, 1.75 mg) ships from national specialty pharmacies like Optum Specialty, Accredo, and AllianceRx Walgreens. These pharmacies handle prior authorization paperwork, offer patient assistance enrollment, and ship temperature-controlled packages to any North Dakota address within 2 to 5 business days.

503A compounding pharmacies. North Dakota licenses 503A pharmacies to compound patient-specific prescriptions, including bremelanotide for subcutaneous injection. The North Dakota Board of Pharmacy requires a valid prescription naming the individual patient. Compounded bremelanotide typically costs less than branded Vyleesi, ranging from $50 to $150 per month depending on dose count and pharmacy. The compounded form arrives as a multi-use vial with insulin syringes rather than an autoinjector pen.

Retail specialty counters. Some Walgreens and CVS locations in Fargo, Bismarck, and Grand Forks stock or can order branded Vyleesi. Availability is inconsistent, so calling ahead or using the manufacturer's pharmacy locator saves time.

Shipping timelines: branded product from specialty pharmacies averages 3 to 5 business days after prior authorization clears. Compounded product ships within 2 to 4 business days from order confirmation.

Insurance Coverage and Prior Authorization

North Dakota Medicaid does not cover Vyleesi. Patients on Medicaid must either pay out-of-pocket for branded product (approximately $850 to $950 for four autoinjectors without coupons) or use a 503A compounding pharmacy 3.

Commercial insurers (Blue Cross Blue Shield of North Dakota, Sanford Health Plan, Medica) may cover Vyleesi after prior authorization. The typical PA documentation bundle includes:

• Confirmed HSDD diagnosis with FSDS-R score
• Documentation that the condition is not attributable to a medical condition, medication, or relationship factor
• Trial and failure or contraindication to at least one alternative (flibanserin/Addyi is the most commonly required step therapy)
• Baseline blood pressure within normal limits
• Prescriber attestation that the patient is premenopausal

PA turnaround in North Dakota averages 3 to 7 business days. If denied, the prescriber can submit a peer-to-peer review. The Cosette Pharmaceuticals patient support program (VyleesiConnect) offers co-pay assistance reducing out-of-pocket to $0 to $50 per fill for commercially insured patients.

Who Can Prescribe in North Dakota

Three provider categories can write a Vyleesi prescription in North Dakota: physicians (MD/DO), nurse practitioners, and physician assistants.

Physicians. Any MD or DO with an active North Dakota license can prescribe bremelanotide. OB/GYNs, family medicine physicians, and sexual medicine specialists are the most common prescribers. No DEA registration is needed since bremelanotide is non-scheduled.

Nurse practitioners. North Dakota grants NPs full practice authority after completing 2,000 collaborative hours. Post-transition NPs prescribe independently. Women's health NPs and family NPs both qualify, and many staff telehealth platforms that serve rural ND communities.

Physician assistants. PAs prescribe under a collaborative agreement. The supervising physician need not co-sign individual prescriptions for non-controlled medications in North Dakota, but the agreement must be on file with the Board.

The International Society for the Study of Women's Sexual Health (ISSWSH) recommends that prescribers of HSDD pharmacotherapy complete training in biopsychosocial assessment of female sexual dysfunction 4. This is a recommendation, not a North Dakota regulatory requirement.

Self-Administration and Dosing Instructions

Vyleesi is injected subcutaneously into the abdomen or anterior thigh at least 45 minutes before anticipated sexual activity. The autoinjector delivers a fixed 1.75 mg dose. Patients should not use more than one injection in 24 hours or more than 8 injections in a calendar month 1.

First-dose nausea affects approximately 40% of patients. The FDA label recommends taking the first dose in a clinical setting or with anti-nausea medication available. In practice, most telehealth prescribers counsel patients to have ondansetron 4 mg on hand for the first two to three uses. Nausea frequency drops to approximately 2 to 4% by the sixth dose based on RECONNECT open-label extension data.

Injection technique is straightforward: clean the site, pinch skin, insert at 45 to 90 degrees, press the autoinjector button, hold for 5 seconds. Rotate injection sites to reduce lipodystrophy risk. Store pens at room temperature (20 to 25°C); do not freeze.

Transferring an Existing Prescription to North Dakota

Patients relocating to North Dakota or visiting for extended periods can transfer a Vyleesi prescription from another state. North Dakota Board of Pharmacy rules allow inbound prescription transfers for non-controlled medications via the standard pharmacist-to-pharmacist transfer protocol.

The receiving North Dakota pharmacy contacts the originating pharmacy, obtains remaining refill information, and activates the prescription locally. Electronic prescribing across state lines works when the out-of-state prescriber holds a North Dakota license. If they do not, a new evaluation with a North Dakota-licensed provider is required before a new prescription can be issued.

For patients using a national specialty pharmacy (Accredo, Optum), shipping address changes within the U.S. typically require only a phone call. The prescription itself does not need re-issuance because the dispensing pharmacy's license covers multi-state shipping.

Timeline: From Consultation to First Dose

A realistic timeline for a new North Dakota patient:

• Day 1: Telehealth consultation scheduled and completed (same-day appointments available on many platforms)
• Day 1 to 2: Lab orders placed; patient completes blood draw
• Day 3 to 4: Lab results reviewed; prescription issued
• Day 4 to 5: Prior authorization submitted (if using insurance)
• Day 7 to 12: PA approved; pharmacy ships
• Day 9 to 14: Patient receives medication

Without insurance (cash pay through 503A pharmacy), the process compresses to 5 to 7 days total because prior authorization is eliminated.

Safety Considerations Specific to North Dakota Patients

North Dakota's climate creates one practical consideration: storage. Branded Vyleesi autoinjectors must be kept between 20 and 25°C. During winter months when indoor heating may dry out packaging, and during transport from a mailbox in sub-zero conditions, patients should bring packages inside immediately. Bremelanotide peptide degrades if frozen.

The other consideration is altitude and cardiovascular load. North Dakota's elevation is modest (under 3,500 feet statewide), so the transient blood pressure elevation from bremelanotide does not compound with altitude-related cardiovascular stress as it might in Colorado or Utah.

Patients taking antihypertensives should monitor home blood pressure for the first three doses to confirm the transient pressor effect remains within safe bounds. The FDA reports no clinically significant drug interactions with common antihypertensives, but advises against use with naltrexone (blocks melanocortin signaling) 1.